Condition: Pancreatic Ductal Adenocarcinoma (PDAC) · Sponsor: Qilu Pharmaceutical Co., Ltd.
The purpose of this study is to evaluate the efficacy and safety of CEND-1 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo as first-line treatment in patients with Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma.
This description comes directly from the study's public registry record.
Jianming Xu, M.D · 13910866712 · Jianmingxu2014@163.com
Always discuss trial participation with your own doctor first.
| Chinese People's Liberation Army (PLA) General Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06261359